周二盘后交易中，生物制药公司BridgeBio Pharma（股票代码：BBIO）股价大跌12.42%，主要原因是该公司公布的季度业绩未能达到分析师预期。
根据公司发布的财报，截至6月30日的季度中，BridgeBio Pharma调整后每股亏损为0.95美元，高于分析师平均预期的0.84美元亏损。尽管公司营收同比大幅增长4999.9%，达到1.1057亿美元，超过了分析师预期的9141万美元，但巨额亏损仍然令投资者感到失望。该季度公司净亏损高达1.819亿美元。
值得注意的是，在此次财报公布之前，BridgeBio Pharma的股价表现相当强劲。过去一个季度，公司股价上涨了10.6%，今年迄今为止更是上涨了74.0%。尽管本次业绩不及预期，但华尔街分析师对公司前景仍保持乐观态度。目前，分析师对该公司股票的平均评级为"买入"，其中20个评级为"强烈买入"或"买入"，1个为"持有"，没有"卖出"或"强烈卖出"评级。分析师给出的12个月目标价中位数为60.00美元，较最新收盘价47.75美元高出约20.4%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.